Octreotide - Qrono
Alternative Names: Octreotide Qx; QR 107Latest Information Update: 28 Sep 2021
Price :
$50 *
At a glance
- Originator Qrono
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2021 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral, Injection)
- 16 Aug 2017 Chemical structure information added
- 02 Aug 2017 Octreotide- Qrono is available for licensing as of 02 Aug 2017. http://qrono.com/pipeline/ (Qrono pipeline, August 2017)